Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul 1;39(8):1014-1017.
doi: 10.1097/QAD.0000000000004153. Epub 2025 Mar 6.

'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV

Gianmaria Baldin  1   2 , Pierluigi Francesco Salvo  2 , Rosa Anna Passerotto  2 , Valentina Iannone  2 , Francesco Lamanna  2 , Andrea Carbone  2 , Damiano Farinacci  1 , Francesca Lombardi  1 , Alberto Borghetti  3 , Simona Di Giambenedetto  1   2 , Carlo Torti  1   2 , Arturo Ciccullo  4
Affiliations
Observational Study

'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV

Gianmaria Baldin et al. AIDS. .

Abstract

Objectives: Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine is a well tolerated option for simplification in people with HIV (PWH). We aimed to assess long-time effectiveness and safety in our cohort.

Methods: We performed an observational study enrolling HIV-1-infected, virologically suppressed PWH, switching to dolutegravir plus lamivudine. Exclusion criteria were HBV-coinfection and the presence of the M184V mutation before the simplification. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥200 copies/ml or by two consecutive HIV-RNA ≥ 50 copies/ml) and treatment discontinuation (TD, defined as the interruption of either 3TC or DTG).

Results: Six hundred thirty-one PWH were considered for the analysis: 446 were males (70.7%), with a median age of 51.1 years [interquartile range (IQR) 42.6-57.6]. Estimated probabilities of maintaining virological suppression at 192 and 384 weeks were 95.1% [95% confidence interval (CI) 92.0-96.2] and 91.5% (95% CI 87.1-94.4), respectively. At multivariable analysis, including zenith HIV-RNA, time of virological suppression before switch, risk factors for HIV infection and age, only intravenous drug users (IDU) [versus other risk factors, adjusted hazard ratio (aHR) 3.58, 95% CI 1.38-9.28, P = 0.009] independently predicted VF. A border-line significant association with VF emerged for age (per 10-years more, aHR 0.72, 95% CI 0.51-1.01, P = 0.058) and zenith HIV-RNA >500 000 cps/ml (versus. <500 000 cps/ml, aHR 2.31, 95% CI 0.98-5.46, P = 0.056).As to treatment tolerability, estimated probabilities of remaining on study regimen at 192 and 384 weeks were 87.8% (95% CI 84.5-90.5) and 85.1% (95% CI 81.0-88.5), respectively.

Conclusions: Our findings confirm the long-term effectiveness and tolerability of dolutegravir plus lamivudine in virologically suppressed PWH.

Keywords: HAART; HIV; dolutegravir; effectiveness; lamivudine; simplification.

PubMed Disclaimer

Conflict of interest statement

A.Ci received fees from ViiV Healthcare and MSD. A.B. has received nonfinancial support from Bristol-Myers Squibb and ViiV Healthcare, and personal fees from Gilead Sciences and Janssen. S.D. G. was a paid consultant or member of advisory boards for Gilead, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme and Bristol-Myers Squibb. All other authors: none to declare.

References

    1. Sax PE, Gathe JC, Jr. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS 2005; 19:563–576. - PubMed
    1. Borghetti A, Ciccullo A, Baldin G, et al. . Shall we dance? Extending TANGO's results to clinical practice. Clin Infect Dis 2020; 71:e200–e201. - PMC - PubMed
    1. Arancòn Pardo A, Moreno Palomino M, Jimenez-Nacher I, et al. . Real-world experience with two-drug regimens in HIV-1-infected patients beyond the indication of clinical trials: 48 weeks’ results. AIDS Res Hum Retroviruses 2021; 37:761–767. - PubMed
    1. Osiyemi O, De Wit S, Wynne B, et al. . Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4- drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO Randomized Trial. Clin Infect Dis 2022; 75:975–986. - PMC - PubMed
    1. European AIDS Clinical Society Guidelines v12.0. Available at: https://www.eacsociety.org/guidelines/eacs-guidelines/.

Publication types

MeSH terms